News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
186,998 Results
Type
Article (32316)
Company Profile (32)
Press Release (154629)
Multimedia
Podcasts (198)
Webinars (21)
Section
Business (47732)
Career Advice (1785)
Deals (9783)
Drug Delivery (149)
Drug Development (30886)
Employer Resources (201)
FDA (6667)
Job Trends (5620)
News (94730)
Policy (12692)
Tag
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (1572)
Accelerated approval (25)
Adcomms (36)
Allergies (53)
Alliances (12947)
ALS (64)
Alzheimer's disease (885)
Antibody-drug conjugate (ADC) (168)
Approvals (6492)
Artificial intelligence (251)
Autoimmune disease (72)
Automation (12)
Bankruptcy (121)
Best Places to Work (4249)
BIOSECURE Act (22)
Biosimilars (118)
Biotechnology (26)
Bladder cancer (60)
Brain cancer (29)
Breast cancer (250)
Cancer (1891)
Cardiovascular disease (218)
Career advice (1518)
Career pathing (40)
CAR-T (131)
CDC (58)
Celiac Disease (1)
Cell therapy (336)
Cervical cancer (11)
Clinical research (24802)
Collaboration (591)
Company closure (4)
Compensation (122)
Complete response letters (57)
COVID-19 (2309)
CRISPR (37)
C-suite (212)
Cystic fibrosis (68)
Data (2031)
Decentralized trials (2)
Denatured (73)
Depression (83)
Diabetes (238)
Diagnostics (2133)
Digital health (13)
Diversity (13)
Diversity, equity & inclusion (48)
Drug discovery (105)
Drug pricing (212)
Drug shortages (34)
Duchenne muscular dystrophy (129)
Earnings (17330)
Editorial (65)
Employer branding (25)
Employer resources (169)
Events (23203)
Executive appointments (231)
FDA (7643)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (6)
Frontotemporal dementia (10)
Funding (473)
Gene editing (93)
Generative AI (31)
Gene therapy (386)
GLP-1 (905)
Government (3550)
Grass and pollen (3)
Guidances (161)
Healthcare (6214)
HIV (40)
Huntington's disease (39)
IgA nephropathy (42)
Immunology and inflammation (211)
Immuno-oncology (36)
Indications (32)
Infectious disease (2459)
Inflammatory bowel disease (104)
Inflation Reduction Act (14)
Influenza (45)
Intellectual property (60)
Interviews (354)
IPO (3926)
IRA (60)
Job creations (1341)
Job search strategy (1197)
JPM (70)
Kidney cancer (11)
Labor market (93)
Layoffs (614)
Leadership (40)
Legal (2490)
Liver cancer (41)
Longevity (5)
Lung cancer (271)
Lymphoma (140)
Machine learning (24)
Management (65)
Manufacturing (350)
MASH (84)
Medical device (3844)
Medtech (3860)
Mergers & acquisitions (6201)
Metabolic disorders (874)
Multiple sclerosis (85)
NASH (21)
Neurodegenerative disease (193)
Neuropsychiatric disorders (67)
Neuroscience (1508)
Neurotech (1)
NextGen: Class of 2026 (2452)
Non-profit (1973)
Now hiring (66)
Obesity (551)
Opinion (300)
Ovarian cancer (47)
Pain (74)
Pancreatic cancer (82)
Parkinson's disease (108)
Partnered (22)
Patents (146)
Patient recruitment (85)
Peanut (19)
People (13757)
Pharmaceutical (8)
Pharmacy benefit managers (27)
Phase 1 (6935)
Phase 2 (10590)
Phase 3 (10135)
Pipeline (1802)
Policy (331)
Postmarket research (981)
Preclinical (2553)
Press Release (13)
Prostate cancer (87)
Psychedelics (52)
Radiopharmaceuticals (89)
Rare diseases (524)
Real estate (1603)
Recruiting (78)
Regulatory (8918)
Reports (51)
Research institute (1246)
Resumes & cover letters (278)
Rett syndrome (10)
RNA editing (17)
RSV (57)
Schizophrenia (80)
Series A (87)
Series B (57)
Service/supplier (1)
Sickle cell disease (41)
Special edition (27)
Spinal muscular atrophy (92)
Sponsored (47)
Startups (1340)
Stomach cancer (18)
Supply chain (57)
Tariffs (101)
The Weekly (123)
Vaccines (841)
Venture capital (84)
Weight loss (432)
Women's health (47)
Worklife (22)
Date
Last 7 days (199)
Last 30 days (701)
Last 365 days (9530)
2026 (909)
2025 (9624)
2024 (10841)
2023 (12184)
2022 (16043)
2021 (17099)
2020 (16642)
2019 (15486)
2018 (12600)
2017 (8992)
2016 (8342)
2015 (9070)
2014 (6373)
2013 (4956)
2012 (5197)
2011 (5415)
2010 (4856)
Location
Africa (431)
Alabama (13)
Alaska (2)
Arizona (43)
Arkansas (4)
Asia (11166)
Australia (2079)
California (2871)
Canada (864)
China (315)
Colorado (137)
Connecticut (176)
Delaware (91)
Europe (29341)
Florida (447)
Georgia (86)
Hawaii (1)
Idaho (14)
Illinois (226)
India (20)
Indiana (194)
Iowa (13)
Japan (153)
Kansas (43)
Kentucky (15)
Louisiana (11)
Maine (32)
Maryland (511)
Massachusetts (1963)
Michigan (38)
Minnesota (99)
Mississippi (3)
Missouri (40)
Montana (14)
Nebraska (6)
Nevada (56)
New Hampshire (12)
New Jersey (938)
New Mexico (4)
New York (815)
North Carolina (315)
North Dakota (1)
Northern California (1461)
Ohio (140)
Oklahoma (2)
Oregon (16)
Pennsylvania (473)
Puerto Rico (5)
Rhode Island (13)
South America (497)
South Carolina (8)
Southern California (1072)
Tennessee (42)
Texas (397)
United States (10179)
Utah (64)
Virginia (64)
Washington D.C. (39)
Washington State (245)
West Virginia (2)
Wisconsin (47)
186,998 Results for "motus gi".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Motus GI Reports First Quarter 2024 Financial Results and Provides Corporate Update
Motus GI Holdings, Inc. reported its financial results for the first quarter ended March 31, 2024, and provided a corporate update.
May 14, 2024
·
7 min read
Business
Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.
March 18, 2024
·
9 min read
Press Releases
Cepheid Receives FDA Clearance for Xpert® GI Panel to Support Broad Detection of Gastrointestinal Pathogens
January 20, 2026
·
4 min read
Press Releases
Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI
January 6, 2026
·
6 min read
Motus GI Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu® EVS Gastro
Motus GI Holdings, Inc. (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today that the Pure-Vu® EVS Gastro was successfully used in the first procedure since receiving FDA clearance.
November 10, 2023
·
4 min read
BioMidwest
Motus GI Amends Royalty Agreement
Motus GI Holdings, Inc. announced it has reached an agreement to amend the royalty payment rights and, subsequently, cancelled the royalty rights in exchange for an aggregate of 1,455,641 shares of Motus common stock, effective as of September 12, 2023.
September 14, 2023
·
3 min read
Press Releases
SAGA Diagnostics® Presents Real-World Pathlight™ MRD Data at ASCO GI 2026
January 7, 2026
·
4 min read
Business
Motus GI Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the third quarter ended September 30, 2023, and provided a corporate update.
November 13, 2023
·
8 min read
Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract
Motus GI Holdings, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent (patent # 11904085) titled, “Colon Cleaning System with Automatic Self-Purging Feature.”
February 21, 2024
·
3 min read
Deals
Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds
Motus GI Holdings, Inc. today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 2,933,334 shares of the Company’s common stock.
February 22, 2024
·
4 min read
1 of 18,700
Next
